Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended vs Intermittent Piperacillin-Tazobactam Infusion in Critical Care
NCT04895657Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Jul 2018
- Primary completion
- Jan 2020
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin and tazobactam in Gram-negative bacterial infection (2 arms), sponsored by Ain Shams University. Primary endpoints: Clinical cure at 30 days and Total cost at 30 days. Started Jul 2018; status: completed.
02
Drugs
piperacillintazobactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT04895657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895657.